medigraphic.com
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

2018, Number 1

Next >>

Rev Esp Med Quir 2018; 23 (1)

Prevalence of overexpression of HER2 in gastric cancer at the Centro Médico Nacional 20 de Noviembre

López-Jiménez P, Tenorio-Torres JA, Villegas-Carlos F, Miranda-Aguirre AP, Carbajal-Saldaña B, Domínguez-Reyes CA

Language: Spanish
References: 25
Page: 5-9
PDF size: 114.39 Kb.


ABSTRACT

Background: Gastric cancer ranks second in mortality worldwide, its prognosis is determined by the level of invasion. The advance in the study of the molecular biology of cancer has allowed to identify receptors that stimulate cell proliferation, contributing to the creation of new targeted therapies, avoiding the morbidity of antineoplastic drugs and potentiating tumor control among them, the overexpression of HER2, which has been shown to be a prognostic factor in gastric cancer. Likewise, white therapy has managed to increase survival in these patients. Material and methods: A review was made of the cases of patients with gastric cancer and its clinical-pathological variables, including the overexpression of HER2 in the piece of pathology. Likewise, Kaplan Meier survival and Disease Free Interval curves were calculated for the HER2 expression factor. The prevalence and association of variables of interest were determined. Results: The prevalence of HER2 overexpression in our unit was 9% which is within the globally reported ranges of 5-45%. We found an association of HER2 overexpression with diffuse histology and with disease-free period (PLE). Conclusions: The prevalence of HER2 overexpression is similar to that reported worldwide. Larger studies are required to reliably determine associations with diffuse histology and PLE in our population.


REFERENCES

  1. World Health Organization. GLOBOCAN 2008 WHO. Estimated cancer Incidence, Mortality, Prevalence and Disability-adjusted life years (DALYs) Worldwide in 2008. WHO 2010.

  2. Secretaría de Salud. Compendio del Registro Histopatológico de Neoplasias Malignas en México. México: Dirección General de Epidemiolo- gía, 1994, 1998, 2000 y 2003.

  3. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC Cancer Staging Manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471.

  4. Hallissey MT, Dunn JA, Ward LC, Allum WH. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in respectable gastric cancer: five-year follow-up. Lancet. 1994;343:1309-12.

  5. Gravalos C, Jimeno A. HER 2 in gastric cancer: A new prognositic factor and novel therapeutic target. Ann Oncol. 2008;19:1523-9.

  6. Baselga J, Albanell J, Molina MA, Arribas J. Mechanism of action of trastuzumab and scientific update. Semin Oncol. 2001;28:(Suppl 16):4-11.

  7. Atkins JH, Gershell LJ. Selective anticancer drugs. Nat Rev Drug Discov. 2002;1:491-2.

  8. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Washington DC). 1987;235:177-82.

  9. Press MF, Bernstein L, Thomas P, Meisner LF, Zhou JY, Ma Y, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridisation: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997;15:2894-904.

  10. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Säve-Söderborgh J, Anbazhagan R, et al. Prognostic importance of c-erbB2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 1992;10:1049-56.

  11. Niehans GA, Singleeton TP, Dykoski D, Kiang DT. Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst (Bethesda). 1993;85:1230-5.

  12. Pauletti G, Dankekar S, Rong H, Ramos L, Peng H, Seshadri R, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridisation and immunohistochemistry. J Clin Oncol. 2000;18:3651-64.

  13. Harris LN, Liotcheva V, Broadwater G, Ramirez MJ, Maimonis P, Anderson S, et al. Comparison of methodsof measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol. 2001;19:1698-706.

  14. Baselga J. Is circulating HER-2 more than just a tumor marker? Clin Cancer Res. 2001;7:2605-7.

  15. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010;17:CD004064.

  16. Van Cutsam E, Kang Y, Chung H, Shen L, Sawaki A, Lordick F, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced cancer (GC). J Clin Oncol. 2009;27(Suppl 18) (Suppl; abstr LBA4509)

  17. Terence C. Chua, Neil D. Merrett. Clinicopathologic factors associated with Her2-positive gastric cancer and its impact on survival outcomes – A systematic review. Int J Cancer. 2012:130:2845-56.

  18. National Cancer Institute. Surveillance Epidemiology and End Results (SEER) cancer statistics review 1975-2007: Table 24.15 cancer of the stomach (invasive). Disponible en: http://seer.cancer.gov/csr/1975_2007/ browse_csr.php?section=24&page=sect_24_table.15.html. Último acceso: 30 de septiembre de 2011.

  19. Wang S, Zheng G, Chen L, Xiong B. Effect of HER-2/neu Over-expression on Prognosis in Gastric Cancer: A Meta-analysis. Asian Pac J Cancer Prev. 2011;12(6):1417-23.

  20. Wu H, Rusiecki JA, Zhu K, Potter J, Devesa SS. Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. Cancer Epidemiol Biomarkers Prev. 2009;18(7):1945.

  21. Ikeda Y, Mori M, Kamakura T, Haraguchi Y, Saku M, Sugimachi K. Surgical management of gastric cancer. Br J Cancer. 1995;72(2):424.

  22. Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, et al.; GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303(17):1729-37.

  23. Shah MA, Ajani JA. Gastric cancer – an enigmatic and heterogeneous disease. JAMA. 2010 ;303(17):1753-4.

  24. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Gastric Cancer. May 13, 2012.

  25. D’Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS, et al. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240(5):808-16.




2020     |     www.medigraphic.com